HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

kolektiv Ceske pracovni skupiny pro myeloproliferativni choroby (CZEMP) Selected Research

Essential Thrombocythemia

6/2013[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


kolektiv Ceske pracovni skupiny pro myeloproliferativni choroby (CZEMP) Research Topics

Disease

1Hemorrhage
06/2013
1Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2013
1Essential Thrombocythemia
06/2013
1Thrombocytosis (Thrombocythemia)
06/2013
1Thrombosis (Thrombus)
06/2013
1Primary Myelofibrosis (Myelosclerosis)
06/2013

Drug/Important Bio-Agent (IBA)

1anagrelide (Agrylin)FDA LinkGeneric
06/2013
14- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA
06/2013

Therapy/Procedure

1Therapeutics
06/2013